1. Discovery and mode of action of a novel analgesic β-toxin from the African spider Ceratogyrus darlingi.
- Author
-
Sousa, Silmara R., Wingerd, Joshua S., Brust, Andreas, Bladen, Christopher, Ragnarsson, Lotten, Herzig, Volker, Deuis, Jennifer R., Dutertre, Sebastien, Vetter, Irina, Zamponi, Gerald W., King, Glenn F., Alewood, Paul F., and Lewis, Richard J.
- Subjects
SPIDER venom ,ION channel models ,ELECTROPHYSIOLOGY ,FLUORIMETRY ,PAIN management - Abstract
Spider venoms are rich sources of peptidic ion channel modulators with important therapeutical potential. We screened a panel of 60 spider venoms to find modulators of ion channels involved in pain transmission. We isolated, synthesized and pharmacologically characterized Cd1a, a novel peptide from the venom of the spider Ceratogyrus darlingi. Cd1a reversibly paralysed sheep blowflies (PD
50 of 1318 pmol/g) and inhibited human Cav 2.2 (IC50 2.6 μM) but not Cav 1.3 or Cav 3.1 (IC50 > 30 μM) in fluorimetric assays. In patch-clamp electrophysiological assays Cd1a inhibited rat Cav 2.2 with similar potency (IC50 3 μM) without influencing the voltage dependence of Cav 2.2 activation gating, suggesting that Cd1a doesn’t act on Cav 2.2 as a classical gating modifier toxin. The Cd1a binding site on Cav 2.2 did not overlap with that of the pore blocker ω-conotoxin GVIA, but its activity at Cav 2.2-mutant indicated that Cd1a shares some molecular determinants with GVIA and MVIIA, localized near the pore region. Cd1a also inhibited human Nav 1.1–1.2 and Nav 1.7–1.8 (IC50 0.1–6.9 μM) but not Nav 1.3–1.6 (IC50 > 30 μM) in fluorimetric assays. In patch-clamp assays, Cd1a strongly inhibited human Nav 1.7 (IC50 16 nM) and produced a 29 mV depolarising shift in Nav 1.7 voltage dependence of activation. Cd1a (400 pmol) fully reversed Nav 1.7-evoked pain behaviours in mice without producing side effects. In conclusion, Cd1a inhibited two anti-nociceptive targets, appearing to interfere with Cav 2.2 inactivation gating, associated with the Cav 2.2 α-subunit pore, while altering the activation gating of Nav 1.7. Cd1a was inactive at some of the Nav and Cav channels expressed in skeletal and cardiac muscles and nodes of Ranvier, apparently contributing to the lack of side effects at efficacious doses, and suggesting potential as a lead for development of peripheral pain treatments. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF